Get the Stockscreener App
28.66
0.05%
-0.015
After Hours:
28.62
-0.035
-0.12%
Tema Etf Trust Tema Obesity Cardiometabolic Etf stock is traded at $28.66, with a volume of 2,482.
It is down -0.05% in the last 24 hours and up +2.74% over the past month.
See More
Previous Close:
$28.67
Open:
$28.75
24h Volume:
2,482
Relative Volume:
0.36
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.50%
1M Performance:
+2.74%
6M Performance:
-2.50%
1Y Performance:
-13.17%
1-Day Range:
$28.60
$28.76
1-Week Range:
$28.37
$28.80
52-Week Range:
$25.32
$36.03
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile
Name
Tema Etf Trust Tema Obesity Cardiometabolic Etf
Sector
Industry
Phone
-
Address
-
Compare HRTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTS
Tema Etf Trust Tema Obesity Cardiometabolic Etf
|
28.66 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
308.03 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
625.34 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
628.17 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
243.21 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
556.22 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Latest News
5 Small-cap Biotech ETFs to Watch - Investing News Network
Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Declines By 28.6% - Defense World
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Short Interest Down 60.0% in February - Defense World
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends - ETF Trends
Tema's New VOLT ETF Sparked by AI Revolution - etf.com
Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Nasdaq
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Nasdaq
Tap the Weight-Loss Drug Market With These ETFs - Nasdaq
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - markets.businessinsider.com
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Weight-loss drug forecasts jump to $150 billion as supply grows - Reuters
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
What Is a Healthcare ETF? Everything You Need to Know - ETF.com
The 5 Best Biotech ETFs of 2024 - etf.com
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
Be Thankful — It Could Have Been So Much Worse - Bloomberg.com
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Financials Data
There is no financial data for Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.53%
Cap:
|
Volume (24h):